5,284 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by FORA Capital LLC

Key Points

• FORA Capital LLC has acquired 5,284 shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), valued at approximately $271,000, as part of their new position in the company.
• Several analysts have provided varying ratings and price targets for Tarsus Pharmaceuticals, with a consensus rating of "Moderate Buy" and a target price of $66.67.
• Tarsus Pharmaceuticals reported a quarterly earnings miss, with EPS of ($0.48) compared to a consensus estimate of ($0.33), but revenues of $102.66 million surpassed analyst expectations.

FORA Capital LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,284 shares of the company's stock, valued at approximately $271,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TARS. Toronto Dominion Bank purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $105,714,000. Millennium Management LLC grew its holdings in Tarsus Pharmaceuticals by 189.4% in the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock valued at $35,659,000 after buying an additional 421,495 shares during the period. Nuveen LLC purchased a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at about $13,589,000. D. E. Shaw & Co. Inc. grew its holdings in Tarsus Pharmaceuticals by 100.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 365,544 shares of the company's stock valued at $20,240,000 after buying an additional 183,449 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Tarsus Pharmaceuticals by 6,112.1% in the 1st quarter. Russell Investments Group Ltd. now owns 134,617 shares of the company's stock valued at $6,915,000 after buying an additional 132,450 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Oppenheimer began coverage on Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target for the company. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research note on Tuesday, May 27th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $58.58 on Friday. The firm has a market capitalization of $2.47 billion, a P/E ratio of -25.14 and a beta of 0.79. Tarsus Pharmaceuticals, Inc. has a 1-year low of $25.82 and a 1-year high of $58.95. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. The business's 50-day simple moving average is $45.57 and its 200-day simple moving average is $46.04.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The firm had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer directly owned 818,106 shares of the company's stock, valued at approximately $40,905,300. The trade was a 0.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 8.97% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.